_version_ 1783749892613603328
author Lee, Grace C.
Restrepo, Marcos I.
Harper, Nathan
Manoharan, Muthu Saravanan
Smith, Alisha M.
Meunier, Justin A.
Sanchez-Reilly, Sandra
Ehsan, Aamir
Branum, Anne P.
Winter, Caitlyn
Winter, Lauryn
Jimenez, Fabio
Pandranki, Lavanya
Carrillo, Andrew
Perez, Graciela L.
Anzueto, Antonio
Trinh, Hanh
Lee, Monica
Hecht, Joan M.
Martinez-Vargas, Celida
Sehgal, Raj T.
Cadena, Jose
Walter, Elizabeth A.
Oakman, Kimberly
Benavides, Raymond
Pugh, Jacqueline A.
Letendre, Scott
Steri, Maristella
Orrù, Valeria
Fiorillo, Edoardo
Cucca, Francesco
Moreira, Alvaro G.
Zhang, Nu
Leadbetter, Elizabeth
Agan, Brian K.
Richman, Douglas D.
He, Weijing
Clark, Robert A.
Okulicz, Jason F.
Ahuja, Sunil K.
author_facet Lee, Grace C.
Restrepo, Marcos I.
Harper, Nathan
Manoharan, Muthu Saravanan
Smith, Alisha M.
Meunier, Justin A.
Sanchez-Reilly, Sandra
Ehsan, Aamir
Branum, Anne P.
Winter, Caitlyn
Winter, Lauryn
Jimenez, Fabio
Pandranki, Lavanya
Carrillo, Andrew
Perez, Graciela L.
Anzueto, Antonio
Trinh, Hanh
Lee, Monica
Hecht, Joan M.
Martinez-Vargas, Celida
Sehgal, Raj T.
Cadena, Jose
Walter, Elizabeth A.
Oakman, Kimberly
Benavides, Raymond
Pugh, Jacqueline A.
Letendre, Scott
Steri, Maristella
Orrù, Valeria
Fiorillo, Edoardo
Cucca, Francesco
Moreira, Alvaro G.
Zhang, Nu
Leadbetter, Elizabeth
Agan, Brian K.
Richman, Douglas D.
He, Weijing
Clark, Robert A.
Okulicz, Jason F.
Ahuja, Sunil K.
author_sort Lee, Grace C.
collection PubMed
description BACKGROUND: The risk of severe coronavirus disease 2019 (COVID-19) varies significantly among persons of similar age and is higher in males. Age-independent, sex-biased differences in susceptibility to severe COVID-19 may be ascribable to deficits in a sexually dimorphic protective attribute that we termed immunologic resilience (IR). OBJECTIVE: We sought to examine whether deficits in IR that antedate or are induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection independently predict COVID-19 mortality. METHODS: IR levels were quantified with 2 novel metrics: immune health grades (IHG-I [best] to IHG-IV) to gauge CD8(+) and CD4(+) T-cell count equilibrium, and blood gene expression signatures. IR metrics were examined in a prospective COVID-19 cohort (n = 522); primary outcome was 30-day mortality. Associations of IR metrics with outcomes in non–COVID-19 cohorts (n = 13,461) provided the framework for linking pre–COVID-19 IR status to IR during COVID-19, as well as to COVID-19 outcomes. RESULTS: IHG-I, tracking high-grade equilibrium between CD8(+) and CD4(+) T-cell counts, was the most common grade (73%) among healthy adults, particularly in females. SARS-CoV-2 infection was associated with underrepresentation of IHG-I (21%) versus overrepresentation (77%) of IHG-II or IHG-IV, especially in males versus females (P < .01). Presentation with IHG-I was associated with 88% lower mortality, after controlling for age and sex; reduced risk of hospitalization and respiratory failure; lower plasma IL-6 levels; rapid clearance of nasopharyngeal SARS-CoV-2 burden; and gene expression signatures correlating with survival that signify immunocompetence and controlled inflammation. In non–COVID-19 cohorts, IR-preserving metrics were associated with resistance to progressive influenza or HIV infection, as well as lower 9-year mortality in the Framingham Heart Study, especially in females. CONCLUSIONS: Preservation of immunocompetence with controlled inflammation during antigenic challenges is a hallmark of IR and associates with longevity and AIDS resistance. Independent of age, a male-biased proclivity to degrade IR before and/or during SARS-CoV-2 infection predisposes to severe COVID-19.
format Online
Article
Text
id pubmed-8425719
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Mosby
record_format MEDLINE/PubMed
spelling pubmed-84257192021-09-09 Immunologic resilience and COVID-19 survival advantage Lee, Grace C. Restrepo, Marcos I. Harper, Nathan Manoharan, Muthu Saravanan Smith, Alisha M. Meunier, Justin A. Sanchez-Reilly, Sandra Ehsan, Aamir Branum, Anne P. Winter, Caitlyn Winter, Lauryn Jimenez, Fabio Pandranki, Lavanya Carrillo, Andrew Perez, Graciela L. Anzueto, Antonio Trinh, Hanh Lee, Monica Hecht, Joan M. Martinez-Vargas, Celida Sehgal, Raj T. Cadena, Jose Walter, Elizabeth A. Oakman, Kimberly Benavides, Raymond Pugh, Jacqueline A. Letendre, Scott Steri, Maristella Orrù, Valeria Fiorillo, Edoardo Cucca, Francesco Moreira, Alvaro G. Zhang, Nu Leadbetter, Elizabeth Agan, Brian K. Richman, Douglas D. He, Weijing Clark, Robert A. Okulicz, Jason F. Ahuja, Sunil K. J Allergy Clin Immunol Covid-19 BACKGROUND: The risk of severe coronavirus disease 2019 (COVID-19) varies significantly among persons of similar age and is higher in males. Age-independent, sex-biased differences in susceptibility to severe COVID-19 may be ascribable to deficits in a sexually dimorphic protective attribute that we termed immunologic resilience (IR). OBJECTIVE: We sought to examine whether deficits in IR that antedate or are induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection independently predict COVID-19 mortality. METHODS: IR levels were quantified with 2 novel metrics: immune health grades (IHG-I [best] to IHG-IV) to gauge CD8(+) and CD4(+) T-cell count equilibrium, and blood gene expression signatures. IR metrics were examined in a prospective COVID-19 cohort (n = 522); primary outcome was 30-day mortality. Associations of IR metrics with outcomes in non–COVID-19 cohorts (n = 13,461) provided the framework for linking pre–COVID-19 IR status to IR during COVID-19, as well as to COVID-19 outcomes. RESULTS: IHG-I, tracking high-grade equilibrium between CD8(+) and CD4(+) T-cell counts, was the most common grade (73%) among healthy adults, particularly in females. SARS-CoV-2 infection was associated with underrepresentation of IHG-I (21%) versus overrepresentation (77%) of IHG-II or IHG-IV, especially in males versus females (P < .01). Presentation with IHG-I was associated with 88% lower mortality, after controlling for age and sex; reduced risk of hospitalization and respiratory failure; lower plasma IL-6 levels; rapid clearance of nasopharyngeal SARS-CoV-2 burden; and gene expression signatures correlating with survival that signify immunocompetence and controlled inflammation. In non–COVID-19 cohorts, IR-preserving metrics were associated with resistance to progressive influenza or HIV infection, as well as lower 9-year mortality in the Framingham Heart Study, especially in females. CONCLUSIONS: Preservation of immunocompetence with controlled inflammation during antigenic challenges is a hallmark of IR and associates with longevity and AIDS resistance. Independent of age, a male-biased proclivity to degrade IR before and/or during SARS-CoV-2 infection predisposes to severe COVID-19. Mosby 2021-11 2021-09-08 /pmc/articles/PMC8425719/ /pubmed/34508765 http://dx.doi.org/10.1016/j.jaci.2021.08.021 Text en Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Covid-19
Lee, Grace C.
Restrepo, Marcos I.
Harper, Nathan
Manoharan, Muthu Saravanan
Smith, Alisha M.
Meunier, Justin A.
Sanchez-Reilly, Sandra
Ehsan, Aamir
Branum, Anne P.
Winter, Caitlyn
Winter, Lauryn
Jimenez, Fabio
Pandranki, Lavanya
Carrillo, Andrew
Perez, Graciela L.
Anzueto, Antonio
Trinh, Hanh
Lee, Monica
Hecht, Joan M.
Martinez-Vargas, Celida
Sehgal, Raj T.
Cadena, Jose
Walter, Elizabeth A.
Oakman, Kimberly
Benavides, Raymond
Pugh, Jacqueline A.
Letendre, Scott
Steri, Maristella
Orrù, Valeria
Fiorillo, Edoardo
Cucca, Francesco
Moreira, Alvaro G.
Zhang, Nu
Leadbetter, Elizabeth
Agan, Brian K.
Richman, Douglas D.
He, Weijing
Clark, Robert A.
Okulicz, Jason F.
Ahuja, Sunil K.
Immunologic resilience and COVID-19 survival advantage
title Immunologic resilience and COVID-19 survival advantage
title_full Immunologic resilience and COVID-19 survival advantage
title_fullStr Immunologic resilience and COVID-19 survival advantage
title_full_unstemmed Immunologic resilience and COVID-19 survival advantage
title_short Immunologic resilience and COVID-19 survival advantage
title_sort immunologic resilience and covid-19 survival advantage
topic Covid-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425719/
https://www.ncbi.nlm.nih.gov/pubmed/34508765
http://dx.doi.org/10.1016/j.jaci.2021.08.021
work_keys_str_mv AT leegracec immunologicresilienceandcovid19survivaladvantage
AT restrepomarcosi immunologicresilienceandcovid19survivaladvantage
AT harpernathan immunologicresilienceandcovid19survivaladvantage
AT manoharanmuthusaravanan immunologicresilienceandcovid19survivaladvantage
AT smithalisham immunologicresilienceandcovid19survivaladvantage
AT meunierjustina immunologicresilienceandcovid19survivaladvantage
AT sanchezreillysandra immunologicresilienceandcovid19survivaladvantage
AT ehsanaamir immunologicresilienceandcovid19survivaladvantage
AT branumannep immunologicresilienceandcovid19survivaladvantage
AT wintercaitlyn immunologicresilienceandcovid19survivaladvantage
AT winterlauryn immunologicresilienceandcovid19survivaladvantage
AT jimenezfabio immunologicresilienceandcovid19survivaladvantage
AT pandrankilavanya immunologicresilienceandcovid19survivaladvantage
AT carrilloandrew immunologicresilienceandcovid19survivaladvantage
AT perezgracielal immunologicresilienceandcovid19survivaladvantage
AT anzuetoantonio immunologicresilienceandcovid19survivaladvantage
AT trinhhanh immunologicresilienceandcovid19survivaladvantage
AT leemonica immunologicresilienceandcovid19survivaladvantage
AT hechtjoanm immunologicresilienceandcovid19survivaladvantage
AT martinezvargascelida immunologicresilienceandcovid19survivaladvantage
AT sehgalrajt immunologicresilienceandcovid19survivaladvantage
AT cadenajose immunologicresilienceandcovid19survivaladvantage
AT walterelizabetha immunologicresilienceandcovid19survivaladvantage
AT oakmankimberly immunologicresilienceandcovid19survivaladvantage
AT benavidesraymond immunologicresilienceandcovid19survivaladvantage
AT pughjacquelinea immunologicresilienceandcovid19survivaladvantage
AT immunologicresilienceandcovid19survivaladvantage
AT letendrescott immunologicresilienceandcovid19survivaladvantage
AT sterimaristella immunologicresilienceandcovid19survivaladvantage
AT orruvaleria immunologicresilienceandcovid19survivaladvantage
AT fiorilloedoardo immunologicresilienceandcovid19survivaladvantage
AT cuccafrancesco immunologicresilienceandcovid19survivaladvantage
AT moreiraalvarog immunologicresilienceandcovid19survivaladvantage
AT zhangnu immunologicresilienceandcovid19survivaladvantage
AT leadbetterelizabeth immunologicresilienceandcovid19survivaladvantage
AT aganbriank immunologicresilienceandcovid19survivaladvantage
AT richmandouglasd immunologicresilienceandcovid19survivaladvantage
AT heweijing immunologicresilienceandcovid19survivaladvantage
AT clarkroberta immunologicresilienceandcovid19survivaladvantage
AT okuliczjasonf immunologicresilienceandcovid19survivaladvantage
AT ahujasunilk immunologicresilienceandcovid19survivaladvantage